- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | NSE - ProSomnus, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 1 | SEC Filings | ||
| 18.04. | ProSomnus, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.03. | ProSomnus, Inc. Common Stock (OSA) Q4 2023 Earnings Call Transcript | 1 | Insider Monkey | ||
| 27.03. | ProSomnus, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 26.03. | ProSomnus reports Q4 results | 1 | Seeking Alpha | ||
| 26.03. | ProSomnus Sleep Technologies, Inc.: ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results | 112 | GlobeNewswire (Europe) | PLEASANTON, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), the leading non-CPAP therapy for the treatment of Obstructive Sleep Apnea (OSA), today announced financial results... ► Artikel lesen | |
| 22.03. | ProSomnus, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.03. | ProSomnus Sleep Technologies, Inc.: ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call | 1 | GlobeNewswire (USA) | ||
| 22.02. | ProSomnus Sleep Technologies, Inc.: ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea | 149 | GlobeNewswire (Europe) | PLEASANTON, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the "Company"), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy, announced results of its pilot study... ► Artikel lesen | |
| 16.02. | ProSomnus, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.01. | ProSomnus Sleep Technologies, Inc.: ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices | 261 | GlobeNewswire (Europe) | PLEASANTON, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the "Company"), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy, announced that the company is well-positioned... ► Artikel lesen | |
| 19.12.23 | Why Is Sleep Devices Focused ProSomnus Stock Soaring Today? | 3 | Benzinga.com | ||
| 12.12.23 | ProSomnus, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 11.12.23 | ProSomnus, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.11.23 | ProSomnus, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 14.11.23 | ProSomnus, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 10.11.23 | Prosomnus Inc reports results for the quarter ended in September - Earnings Summary | 1 | Reuters | ||
| 09.11.23 | ProSomnus GAAP EPS of -$0.70 misses by $0.36, revenue of $7.1M beats by $0.07M | 1 | Seeking Alpha | ||
| 09.11.23 | ProSomnus Sleep Technologies, Inc.: ProSomnus, the Leading Non-CPAP Obstructive Sleep Apnea Therapy, Reports Record Third Quarter 2023 Financial Results | 228 | GlobeNewswire (Europe) | PLEASANTON, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. ("the Company") (NASDAQ: OSA), the leading non-CPAP Obstructive Sleep Apnea Therapy, today announced financial results for the... ► Artikel lesen | |
| 07.11.23 | ProSomnus, Inc. - 8-K, Current Report | 1 | SEC Filings |
Seite:
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ORPEA | 12,582 | -0,66 % | EMEIS PURSUES ITS REFOUNDATION: 2023 Consolidated Financial Results of ORPEA S.A. | Significant improvement in non-financial indicators, with major advances for employees, residents and patients
Health and safety: decline in the work-related accident frequency rate, at 24.8... ► Artikel lesen | |
| NANO-X IMAGING | 8,940 | +0,22 % | Nano-X Imaging Ltd. - 6-K, Report of foreign issuer | ||
| BUTTERFLY NETWORK | 0,780 | +10,56 % | ThinkSono Ltd: ThinkSono Releases Real-Time DVT AI Training Solution for Butterfly Network's Handheld Ultrasound Devices | LONDON, ENGLAND / ACCESSWIRE / April 23, 2024 / ThinkSono, a pioneering provider of AI-driven medical imaging solutions, is proud to announce the release of ThinkSono AI Training, a deep vein thrombosis... ► Artikel lesen | |
| GOODRX | 7,190 | +1,55 % | GoodRx Reports Fourth Quarter and Full Year 2023 Results | SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("GoodRx" or the "Company"), the leading destination for prescription savings in the U.S., has released its financial... ► Artikel lesen | |
| JOINT CORP | 12,230 | +1,24 % | The Joint Corp. Reports Fourth Quarter and Year-end 2023 Financial Results | - Grew 2023 Revenue 16%, System-wide Sales 12%, and System-wide Comp Sales 4% vs. 2022 - - Increased Clinic Count to 935 at Year-end 2023, Initiating Refranchising Program - SCOTTSDALE, Ariz., March... ► Artikel lesen | |
| CARMAT | 3,145 | -0,47 % | CARMAT Announces Its 2023 Annual Results and Provides an Update on Its Progress and Prospects for 2024 | 2023 sales of €2.8 million, i.e. 17 Aeson® implants, including 11 in the last quarter
2024 sales forecast of around €14 million
Active exploration of financing options to extend... ► Artikel lesen | |
| HYPERFINE | 0,845 | +1,68 % | Hyperfine, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results | GUILFORD, Conn., March 21, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable... ► Artikel lesen | |
| PROGYNY | 32,040 | -1,42 % | Progyny, Inc. Announces Details for Its First Quarter 2024 Results Report | ||
| MIMEDX | 6,265 | +0,32 % | Mimedx Group, Cyclacel Pharmaceuticals, Predictive Oncology among healthcare movers | ||
| BIOMERICA | 0,665 | -2,21 % | Biomerica, Inc.: Biomerica Reports Third Quarter 2024 Financial Results | Fiscal Discipline Leads to Improvement as Loss per Share Narrows to $0.27 from $0.40 Amidst Sales Force Expansion for the Nine Months in Fiscal 2024 InFoods IBS Positive Clinical Data to be Presented... ► Artikel lesen | |
| ATRION | 370,00 | -6,09 % | Dividendenbekanntmachungen (14.03.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABRDN PLC GB00BF8Q6K64 0,073 GBP 0,0853 EUR ABRDN PLC ADR US00108N1000 0,3203 USD 0,2925 EUR ACCO BRANDS CORPORATION US00081T1088 0... ► Artikel lesen | |
| ATRICURE | 23,170 | +2,48 % | AtriCure upgraded at Oppenheimer on valuation | ||
| TALKSPACE | 3,120 | +1,30 % | Talkspace Announces Third Quarter 2023 Results | B2B payor revenue grew 132% year-over-year 3Q 2023 Operating expenses of $24.0 million, down 30% year-over-year Reduced Net Loss to $4.4 million and Adjusted EBITDA1 loss to $2.8 million, an improvement... ► Artikel lesen | |
| CASTLE BIOSCIENCES | 20,340 | +4,25 % | Castle Biosciences Inc.: Presentations at EADO Highlight Potential Impact of Castle Biosciences' DecisionDx-Melanoma and DecisionDx-SCC Tests on the Management of Patients with Skin Cancer | If choosing to use a molecular test to rule-out a sentinel lymph node biopsy (SLNB) in patients diagnosed with melanoma, it is important to show that patients foregoing an SLNB have low risk outcomes... ► Artikel lesen | |
| AMWELL | 0,529 | -2,29 % | Amwell Receives Continued Listing Standard Notice From NYSE | Boston, April 04, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leading provider of healthcare software as a service, today announced that it received a notice on April 2, 2024 from the New York... ► Artikel lesen |
Das Unternehmen PROSOMNUS INC kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 0,480 Euro und damit +2,13 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
